All-cause mortality by 8 months following initial registration among all MDR patients, by study period.

<p>Kaplan-Meir curves for time from initial TB case registration to death by all causes among all MDR patients, by study period<b>.</b> Abbreviation: LPA, MTBDR<i>plus</i> line probe assay.</p

DST algorithm by study period.

<p>An illustration of the DST algorithm in the Before LPA period (A) and the After LPA period (B). Abbreviations: DST, drug susceptibility testing; LPA, line probe assay; TB, tuberculosis; MDR-TB, multidrug resistant tuberculosis.</p

Time to treatment and drug susceptibility test turnaround times by study period.

<p>An illustration of critical events in the time to MDR treatment and DST turnaround. Abbreviations: DST, drug susceptibility testing; LPA, MTBDR<i>plus</i> line probe assay; MDR, multi-drug resistant tuberculosis; IQR, inter-quartile range.</p

Time to MDR treatment among MDR-TB patients, by study period.

<p>Kaplan-Meir curves for time from initial sputum collection to MDR treatment by study period, including a modeled Before LPA period where the number of MDR-TB cases during the Before LPA period was augmented to match that observed during the After LPA period. Abbreviations: LPA, MTBDR<i>plus</i> line probe assay; MDR, multidrug resistant tuberculosis.</p

DST by patient category and study period.

<p>A breakdown of whether DST was performed or not, by study period (Before and After LPA) and patient category (New versus Retreatment). Abbreviations: LPA, MTBDR<i>plus</i> line probe assay; DST, drug susceptibility testing.</p

Characteristics of all TB patients and MDR-TB patients at the time of TB diagnosis.

<p>Abbreviations: LPA, MTBDR<i>plus</i> line probe assay, IQR, interquartile range; HIV, human immunodeficiency virus; ART, antiretroviral therapy; TB, tuberculosis.</p>*<p>p values are for comparison of the Before LPA period versus the After LPA period.</p>**<p>CD4 cell counts within 6 months of TB diagnosis were recorded for 502 (75%) during the Before LPA period and 612 (89%) during the After LPA period.</p

Drug resistance by study period.

<p>Abbreviations: LPA, Hain MTBDR<i>plus</i> line probe assay; CI, confidence interval; MDR, multi-drug resistant; INH, isoniazid; RIF, rifampin.</p>*<p>Any resistance refers to resistance to either INH or RIF, or both.</p

Concordance of TST and QFT-GIT results among referred individuals that came to BCHD for LTBI evaluation and had both tests performed.

†<p>Overall, 352 individuals had a TST and interpretable QFT-GIT result available. There was an overall concordance of 52.3%.</p>*<p>8 individuals with negative TST results were referred and evaluated by BCHD. 4 individuals with B-waivers had negative TST, but were referred due to an abnormal CXR; 4 individuals had both TST and QFT-GIT performed by referral source.</p

Factors associated with QFT-GIT test positivity among those tested at BCHD.

<p>Only individuals with QFT-GIT performed by BCHD are included. 11 individuals had blood drawn for QFT-GIT but did not have interpretable results due to insufficient blood volume during venipuncture, sample transportation issues, or processing error. There was 1 indeterminate result.</p><p>°p<0.001 for both univariate and multivariate analysis comparing foreign-born to US born individuals.</p><p>°° P = 0.042 comparing HIV positive to HIV negative individuals.</p>†<p>Referral source was omitted from multivariate regression model due to collinearity with birth country.</p>††<p>p = 0.001 comparing those referred from Refugee health services to those referred from primary care providers/other; p = 0.03 comparing those referred from local health departments to those referred from primary care providers/other.</p

Differences in LTBI diagnosis among referrals to BCHD between study periods and by QFT-GIT test status.

*<p>includes individuals that had QFT-GIT performed by referral source. 11/399 individuals in the post-QFT-GIT period had QFT-GIT drawn but no results available; there was 1 indeterminate result in the post-QFT-GIT-period.</p><p>°p<.001 comparing final diagnosis of LTBI between pre-QFT-GIT and post-QFT-GIT periods.</p><p>°°p = .827 for pre-QFT-GIT period comparing LTBI diagnosis between those with and without a QFT-GIT result; p<.001 in post-QFT-GIT period comparing LTBI diagnosis between those with and without QFT-GIT performed.</p>**<p>p = .81 comparing treatment initiation among those diagnosed with LTBI between pre-QFT-GIT and post-QFT-GIT periods; p = 0.690 comparing treatment initiation between those with and without QFT-GIT performed in the pre-QFT-GIT period; p = .349 comparing treatment intiation between those with and without QFT-GIT performed in the post-QFT-GIT period.</p>†<p>Analysis restricted to those who started an INH X 9 months regimen prior to Nov 30, 2010 or Rifampin X 4 months prior to March 30, 2011 to allow time for completion. p = .606 comparing overall treatment completion between pre-QFT-GIT period and post-QFT-GIT period. p = 0.101 comparing those with and without QFT-GIT performed in the post-QFT-GIT period; p = 0.70 comparing those with and without QFT-GIT in the pre-QFT-GIT period.</p